By JoelAugust 19, 20263 min read

If you've ever watched your child flinch before a mealtime injection, this week's news is worth reading twice: the FDA has approved Afrezza, a rapid-acting inhaled insulin, for children and adolescents ages 6 and older with type 1 diabetes (T1D). This makes Afrezza the first and only needle-free mealtime insulin ever approved for kids.

What Exactly Is Afrezza?

Afrezza is an insulin powder that your child breathes in through a small, pocket-sized inhaler before eating — instead of receiving an injection. It's been available for adults since 2014, but as of May 29, 2026, the FDA officially expanded its approval to the pediatric population for the very first time.

It's important to understand what Afrezza is and isn't. It covers mealtime insulin — the dose your child needs to handle the carbohydrates in a meal. It does not replace long-acting (basal) insulin, so children who currently take a daily background insulin shot or use an insulin pump would still do that. Think of Afrezza as a new option for that one piece of the puzzle: the meal-time dose.

What Does the Science Say?

The FDA's approval was based on results from a clinical trial called INHALE-1, a 26-week study that put Afrezza head-to-head with multiple daily injections of rapid-acting insulin in children and adolescents. Researchers looked at blood-sugar control, safety, and how satisfied families were with the treatment.

New data presented at the American Diabetes Association's 2026 Scientific Sessions showed that children who started the trial with an HbA1c (a 3-month average blood sugar measure) below 9.5% — roughly those with already reasonably managed diabetes — saw particularly good results with Afrezza. Researchers also reported greater treatment satisfaction among patients who reached their blood sugar targets.

Side effects can include a cough or mild throat irritation, and Afrezza is not recommended for children with asthma or chronic lung disease. Always talk with your child's diabetes care team to understand if it's a good fit.

Why This Matters for Families

For many kids, mealtime shots are the most emotionally loaded part of the day. Injections at school, at birthday parties, at sleepovers — these moments can cause real anxiety for children and parents alike. Having an inhaled option doesn't erase all challenges, but it genuinely changes the picture for families where injections are a daily battle.

Breakthrough T1D (formerly JDRF), the leading T1D research organization, called this "a meaningful expansion of the pediatric T1D toolkit — not a replacement for what already works, but one more option for the children and families for whom existing options fall short."

What Should You Do Next?

  • Ask your child's endocrinologist whether Afrezza is appropriate for your child's age, lung health, and diabetes management plan.
  • Check insurance coverage. As with many newer medications, coverage may vary. MannKind, Afrezza's maker, has patient assistance programs worth exploring.
  • Don't make any changes on your own. Switching any part of an insulin routine is a medical decision that needs to be made with your care team.

The Bottom Line

A diagnosis of type 1 diabetes comes with a lot of hard moments. News like this is a reminder that the landscape of T1D care keeps improving — researchers and regulators are listening, and options for our kids are growing. Afrezza won't be the right fit for every child, but for those it helps, mealtime just got a little less scary.

As always, nothing on this blog is medical advice. Please consult your child's diabetes care team before making any changes to their treatment.

Sources

  1. Afrezza Rapid-Acting Inhaled Insulin Approved for Children and Adolescents with T1D